

StrataXRT® Effectiveness in Preventing Radiotherapy-Induced Dermatitis in Breast Cancer



Omidvari, S., Eskandari, Z., Nasrollahi, H., Ahmadloo, N., Ansari, M., Hamed, S. H., Khanjani, N., Kakhodaie, B., Mosalaei, A., & Mohammadianpanah, M. (2022). The Investigation of Prophylactic Effect of StrataXRT Gel on Radiation-Induced Dermatitis in Breast Cancer Patients: A Randomized Clinical Trial. *Middle East Journal of Cancer*, 13(2), 293–298.



Scan to read
the original study

Summary

This **randomized-controlled trial** involved **100 women with breast cancer** who underwent quadrantectomy and received either **StrataXRT® gel or no treatment (=standard) during radiotherapy**. The study focused on **measuring dermatitis area and severity**, evaluating the efficacy of StrataXRT®, in reducing radiation-induced dermatitis.




Figure 1: Grade of dermatitis (RTOG) during the radiotherapy course in the StrataXRT and control groups. Data presented as frequency (%). P-values indicate statistical significance.




Figure 2: Comparison of Mean Radiation-Induced Dermatitis Area between Intervention and Control Groups

Results

- A statistically significant difference ($P = 0.002$) is observed between StrataXRT® and control groups, emphasizing the impact of the StrataXRT® on reducing dermatitis size during radiotherapy.
- Throughout the radiotherapy period, **dermatitis severity was consistently lower in the StrataXRT® group**, throughout radiotherapy, emphasizing its potential effectiveness in preventing and reducing skin reactions.
- No observed side effects of StrataXRT®** were reported by both the physician and the patients, indicating the safety of the intervention.

StrataXRT®: Reasons for Effectiveness

StrataXRT® proves highly effective ($P = 0.002$) with consistently smaller dermatitis areas ($36.88 \text{ cm}^2 \pm 69.93$). Its safety, evidenced by no reported side effects, establishes StrataXRT® as a compelling solution for managing radiation-induced dermatitis during radiotherapy.

Omidvari, S., et al. (2022) states,
"StrataXRT® silicone gel compared to the control group significantly prevented and reduced the rate of radiation-induced dermatitis in the patients with breast cancer that peaked at the fifth week of treatment."

For more information, please contact us at
inquiries@stratpharma.com